NovoCure (NVCR) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NovoCure (NVCR) has outperformed PROCEPT BioRobotics (PRCT) over the past year, losing 10.4% versus a loss of 17.3%. Over five years, PRCT leads with a -30.6% price change compared with -89.0% for NVCR. PROCEPT BioRobotics is the larger company by market cap ($1.42 billion vs $1.25 billion), about 1.1 times the size.
NovoCure converts more of its revenue into profit, with a net margin of -20.8% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCR | PRCT |
|---|---|---|
| Share price | $10.71 | $24.70 |
| Market cap | $1.25B | $1.42B |
| 1-day change | +0.19% | -4.08% |
| YTD return | -17.17% | -21.49% |
| 1-year return | -10.38% | -17.28% |
| 5-year return | -88.96% | -30.64% |
| EPS (TTM) | $-1.06 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $655.35M | $308.05M |
| Revenue growth (YoY) | +8.28% | +37.22% |
| Net income (latest FY) | $-136.23M | $-95.57M |
| Gross margin | 74.54% | 63.70% |
| Operating margin | -23.47% | -33.71% |
| Net margin | -20.79% | -31.02% |
| 52-week high | $21.45 | $38.11 |
| 52-week low | $9.82 | $16.67 |
| Distance from 52-week high | -50.07% | -35.19% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +144.07% | -7.89% |
| Average volume | 1.51M | 1.31M |
| Shares outstanding | 116.92M | 57.54M |
| Employees | 1,605 | 888 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NovoCure is more profitable, keeping -20.8 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs +8.28%).
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
NVCR vs PRCT FAQ
Which is bigger, NovoCure or PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.42B compared with $1.25B for NovoCure (NVCR).
Which stock has performed better over the past year, NVCR or PRCT?
NVCR returned -10.38% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are NovoCure and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.